SGLT2 Inhibitor for Severe Tricuspid Regurgitation (Reduction-TR)

Inclusion Criteria: Participant over 20 years of age who understands the research protocol and has written informed consent Participant with severe tricuspid valve regurgitation Vena contracta width > 0.7cm or effective regurgitant orifice (ERO)≥40mm2 for more than 1 month despite medical treatment Participant with left ventricular ejection fraction ≥ 40% Participant with NYHA class II or more Exclusion Criteria: Patient with severe mitral valve or aortic valve disease Left ventricular ejection fraction less than 40%* Patient with severe pulmonary hypertension (TR Vmax > 4m/s) Patient with acute heart failure or dyspnea of NYHA functional class IV or higher Symptomatic hypotension or systolic blood pressure < 90 mmHg at screening Patient with severe lung disease (asthma, obstructive pulmonary disease, acute pulmonary embolism) Patients with renal failure (Estimated GFR < 30 mL/min/1.73 m2) or on dialysis Patient with Type 1 diabetes If a woman of childbearing potential has not used double contraception Patients with claustrophobia or with metallic implants unsuitable for magnetic resonance imaging Blood AST or ALT value is more than twice the upper limit of normal or symptoms and signs of cirrhosis (history of hepatic coma, history of esophageal varices, history of symptomatic ascites) Life expectancy is less than one year Patient who already take SGLT-2 inhibitor A history of hypersensitivity or allergy to SGLT2 inhibitor